Evaxion Biotech A/S ADR (NASDAQ: EVAX) has seen a decline in its stock price by -5.45 in relation to its previous close of 0.89. However, the company has experienced a -3.86% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-12 that COPENHAGEN, Denmark, November 12, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new positive preclinical data from its ongoing cytomegalovirus (CMV) vaccine program named EVX-V1. The data will be presented today at the 9th International Conference on Vaccines Research & Development, taking place in Boston, USA.
Is It Worth Investing in Evaxion Biotech A/S ADR (NASDAQ: EVAX) Right Now?
Company’s 36-month beta value is -0.34.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The average trading volume of EVAX on December 27, 2024 was 61.56K shares.
EVAX’s Market Performance
EVAX’s stock has seen a -3.86% decrease for the week, with a -43.97% drop in the past month and a -72.35% fall in the past quarter. The volatility ratio for the week is 7.43%, and the volatility levels for the past 30 days are at 13.40% for Evaxion Biotech A/S ADR The simple moving average for the past 20 days is -29.37% for EVAX’s stock, with a -70.96% simple moving average for the past 200 days.
Analysts’ Opinion of EVAX
Many brokerage firms have already submitted their reports for EVAX stocks, with Ladenburg Thalmann repeating the rating for EVAX by listing it as a “Buy.” The predicted price for EVAX in the upcoming period, according to Ladenburg Thalmann is $8 based on the research report published on April 02, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see EVAX reach a price target of $14. The rating they have provided for EVAX stocks is “Buy” according to the report published on February 12th, 2024.
EVAX Trading at -54.10% from the 50-Day Moving Average
After a stumble in the market that brought EVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.78% of loss for the given period.
Volatility was left at 13.40%, however, over the last 30 days, the volatility rate increased by 7.43%, as shares sank -47.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -67.46% lower at present.
During the last 5 trading sessions, EVAX fell by -3.86%, which changed the moving average for the period of 200-days by -71.99% in comparison to the 20-day moving average, which settled at $1.1977. In addition, Evaxion Biotech A/S ADR saw -87.66% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for EVAX
Current profitability levels for the company are sitting at:
- -4.57 for the present operating margin
- 1.0 for the gross margin
The net margin for Evaxion Biotech A/S ADR stands at -3.48. The total capital return value is set at -0.99. Equity return is now at value -803.07, with -84.81 for asset returns.
Currently, EBITDA for the company is -21.4 million with net debt to EBITDA at 0.5. When we switch over and look at the enterprise to sales, we see a ratio of 12.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.80.
Conclusion
In a nutshell, Evaxion Biotech A/S ADR (EVAX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
